{
    "type": "ETF",
    "ucits": true,
    "fund_name": "VanEck Bionic Engineering UCITS ETF",
    "investment_objective": "Replicate the MVIS\u00ae Global Bionic Healthcare ESG Index by investing primarily in underlying equity securities of the Index",
    "primary_asset_class": "Equity",
    "geographic_focus": "Global with some exposure to emerging markets including China (Shanghai and Shenzhen Stock Exchanges)",
    "replication_method": "physical",
    "swaps": true,
    "derivatives": false,
    "leverage": false,
    "inverse": false,
    "complex_factors": [
        "Use of equity swaps and index swaps",
        "Derivative instruments usage (futures, options, currency forwards, NDFs)",
        "Exposure to emerging markets",
        "Sector concentration in medical/dental/vision-related companies",
        "Tracking error and optimisation sampling"
    ],
    "classification": "complex",
    "supporting_data": "The Fund primarily uses physical replication investing directly in underlying equity securities of the MVIS Global Bionic Healthcare ESG Index. However, the KIID and PRIIPs KID explicitly state the Fund may also invest in financial derivative instruments including equity swaps, index swaps, futures, options, currency forwards, and non-deliverable forwards (NDFs). The presence of equity swaps and index swaps, even if limited and for replication or tracking efficiency, triggers the classification as complex under MiFID II. The derivatives are used as an inherent part of the investment strategy rather than solely for risk management, so 'derivatives' is marked false but 'swaps' true, which mandates complexity classification. There is no leverage or inverse exposure. The Fund is UCITS compliant and uses a physical replication approach primarily, with some optimisation sampling. The risk profile is medium-high (5/7) in the PRIIPs KID and high (7/7) in the KIID, reflecting sector concentration risk, liquidity risk, and market risk. The Fund invests in a niche sector (bionic healthcare) with some emerging market exposure, which adds to complexity. Costs are straightforward with no performance fees, and ongoing charges are moderate at 0.55%. No capital protection or structured features are present. The PRIIPs KID does not carry a specific comprehension warning but the use of swaps and derivatives embedded in the strategy, combined with sector concentration and emerging market exposure, supports a complex classification under MiFID II rules."
}